How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-bacterial-peritonitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Complicated Bacterial Peritonitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complicated Bacterial Peritonitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Bacterial Peritonitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tygacil	TIGECYCLINE	Fresenius Kabi	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 3 drugs in Complicated Bacterial Peritonitis
· 3 drugs in Complicated Bacterial Peritonitis
Bayer AG · 1 drug in Complicated Bacterial Peritonitis
Bristol-Myers Squibb · 1 drug in Complicated Bacterial Peritonitis
Fresenius Kabi · 1 drug in Complicated Bacterial Peritonitis
Pfizer · 1 drug in Complicated Bacterial Peritonitis
Poitiers University Hospital · 1 drug in Complicated Bacterial Peritonitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Complicated Bacterial Peritonitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Bacterial Peritonitis:

Cite this brief

Drug Landscape (2026). Complicated Bacterial Peritonitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-bacterial-peritonitis. Accessed 2026-06-10.

Complicated Bacterial Peritonitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing